Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of Circulating Tumor Cells as an Early Predictive Marker of Response to a First Line Treatment Based on an Anti-Human Epidermal Growth Factor Receptor (HER), Cetuximab, in Patients With Inoperable Recurrent and/or Metastatic Head-and-neck Squamous-cell Carcinoma.

NCT02119559 is registered in ClinicalTrials.gov with University Hospital, Montpellier as lead sponsor.

NCT NCT02119559
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02119559 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of Circulating Tumor Cells as an Early Predictive Marker of Response to a First Line Treatment Based on an Anti-Human Epidermal Growth Factor Receptor (HER), Cetuximab, in Patients With Inoperable Recurrent and/or Metastatic Head-and-neck Squamous-cell Carcinoma.
Lead sponsor
University Hospital, Montpellier
Phase
Not applicable
Overall status
Unknown status
Start date
September 30, 2012
Completion date
March 31, 2018
Enrollment
115 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic head-and-neck squamous-cell carcinoma